Latin America's leading dedicated cancer centre, founded in 1953, with a large research institute and the region's biggest oncology residency.
A.C. Camargo Cancer Center was founded in São Paulo in 1953 by Antônio Prudente and his wife Carmen through the Fundação Antônio Prudente and is the largest cancer-only hospital in Latin America, combining care, teaching and research. It is known for surgical oncology (head and neck, breast, sarcoma, colorectal and hepatobiliary), one of the region's first robotic surgery programmes, a large hereditary cancer service that characterised the Brazilian TP53 R337H founder mutation in Li-Fraumeni syndrome, and the International Research Center (CIPE) for genomics, bioinformatics and clinical trials. A.C. Camargo runs Brazil's largest oncology residency and fellowship programme and a cancer registry that has tracked outcomes since the 1950s.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to AC Camargo Hospital, including child institutions. 354 works · 2,437 citations · 73% open access · 10% clinical trials · 3% reviews.
Shares Li-Fraumeni syndrome (germline TP53), Hereditary cancer syndromes, Germline (hereditary) testing, TP53.
Shares Robotic & minimally invasive surgery, Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Melanoma.
Shares Robotic & minimally invasive surgery, Comprehensive genomic profiling, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
Shares Robotic & minimally invasive surgery, Comprehensive genomic profiling, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
Shares Germline (hereditary) testing, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Hereditary cancer syndromes, Germline (hereditary) testing.
Shares Li-Fraumeni syndrome (germline TP53), Germline (hereditary) testing, TP53.
Shares Germline (hereditary) testing, HR-positive / HER2-negative breast cancer, Colorectal cancer.